Actuate Therapeutics, Inc. · NASDAQ:ACTU
Actuate Therapeutics — Investor Presentation (September 2026)
17 slides from Actuate Therapeutics's investor presentation, September 2026
Slide 1: Corporate Overview
Corporate Overview September 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about us, including our clinical trials and development plans, and our industry, that are based on management’s beliefs and assumptions and on information currently available to our management. The words “anticipate,” “
Slide 3: Elraglusib – “Pipeline in a Molecule”
Elraglusib – “Pipeline in a Molecule” Therapeutic Potential Across a Broad Range of Cancers Elraglusib is a class-leading GSK-3β inhibitor with a novel, multimodal MOA Clinical trials in 500+ patients resulted in significant increases in survival and complete responses in multiple difficult-to-treat
Slide 4: Significantly Improves OS in a Most Difficult to Treat Cancer
Elraglusib Significantly Improves OS in a Most Difficult to Treat Cancer Doubled percentage of 1L mPDAC patients alive at one year in international Phase 2 RCT 1.0 GnP Elraglusib + GnP 0.8 Survival Probability 0.6 mOS 12-month OS +40.2% 44.4% 0.4 0.2 22.3% 24-month OS 12.9% 0.0 2.6% 0 4 8 12 16 20 2
Slide 5: Elraglusib Development Strategy
Elraglusib Development Strategy Expand Pipeline Potential with Elraglusib Oral Tablet Initiate clinical trials to expand into additional high value / blockbuster indications Advance Pathway to be a SOC Backbone in PDAC Complete nonclinical research assessing potential synergy for combination use of
Slide 6: Elraglusib Targets a Unique Pathway vs RAS/RAF/MEK
Elraglusib Targets a Unique Pathway vs RAS/RAF/MEK RAS pathway inhibitors alone target driver mutations, Elraglusib targets cancer survival pathways with treatment escape nodes on NF-κB pathway GSK-3β • Sotorasib • Dabrafenib • Adagrasib RAS RAF • Encorafenib X Elraglusib • Daraxonrasib • Vemurafeni
Slide 7: Elraglusib Potentiates Antitumor Effects of Zoldonrasib and Daraxonrasib
Elraglusib Potentiates Antitumor Effects of Zoldonrasib and Daraxonrasib Consistent greater-than-additive activity across mouse and human pancreatic cancer cell lines Zoldonrasib + Elraglusib Daraxonrasib + Elraglusib KRAS G12D-selective inhibitor RAS(ON) multi-selective inhibitor 20 / 20 4/4 models
Slide 8: Elraglusib Significantly Improves Survival with Once Weekly IV Dosing
Elraglusib Significantly Improves Survival with Once Weekly IV Dosing Elraglusib + GnP doubled 1-year OS vs. GnP alone (p=0.0004) 2.5x increase in 1-year OS in patients with liver metastases (p=0.0003) Elraglusib + SOC (GnP) improved median OS by 40% (HR: 0.62; p=0.02) Greater benefit seen in patien
Slide 9: Greater Elraglusib Exposure Drives Improved OS Outcomes
Greater Elraglusib Exposure Drives Improved OS Outcomes Target Therapeutic IV Dose Identified PK analyses showed patients exceeding exposure Cavg of 210 ng/ml with significantly better outcomes (HR= 0.48) ~ 60% of Elra QW patients achieve target exposure Multivariable Cox Proportional Hazards Analys
Slide 10: Oral Tablet Provides Expedited Pathway to High Dose Exposure
Oral Tablet Provides Expedited Pathway to High Dose Exposure Increased frequency of dosing could further improve OS benefit Analysis demonstrates 9.3 mpk QW as Proportion of Patients Achieving Exposure Threshold Minimally Effective Dose (MED). ~85% of elraglusib 2QW patients vs ~60% QW patients achi
Slide 11: Elraglusib Tablet to Expand Portfolio of Blockbuster Indications
Elraglusib Tablet to Expand Portfolio of Blockbuster Indications Oral tablets could replace and improve treatment vs IV infusion Increase overall exposure with daily dosing IND clearance received from FDA to initiate Ph1/2 study Potential first clinical candidate indications include: Metastatic CPI
Slide 12: Elraglusib in Rare Pediatric Cancers
Elraglusib in Rare Pediatric Cancers
Slide 13: EWS and NBL: Rare Diseases with High Unmet Need
EWS and NBL: Rare Diseases with High Unmet Need High Unmet Need Ewing Sarcoma (EWS): Neuroblastoma (NBL): 5-year survival: • Leading cause of cancer mortality in peds < 5 yr • 10-15% for relapsed/refractory or after recurrence 1 • Survival rates ~ 50%3 • 7% for patients with disease-free interval <2
Slide 14: Durable Responses in Heavily Pre-treated Ewing Sarcoma Patients
Durable Responses in Heavily Pre-treated Ewing Sarcoma Patients Phase 1 Solid Tumor Study (n=40) 9 elra monotherapy, 12 elra + irinotecan, 19 elra + cyclophosphamide/topotecan Elraglusib + cyclo/topo patients • 10/19 patients responded/achieved disease control • 12 EWS, 6 R/R patients responded/achi
Slide 15: Clinical Data in NBL Support Participation in BEACON2 Trial
Clinical Data in NBL Support Participation in BEACON2 Trial Background Complete Response ~38% patients with advanced • Last line NBL patient with unfavorable relapsed/refractory disease responded molecular profile with stable disease or better in Phase 1 • Achieved CR within 9 cycles clinical study
Slide 16: Anticipated Program Milestones Through 2027
Anticipated Program Milestones Through 2027 Synchronized progress across Elra + RAS combinations, Elraglusib Oral Tablet, and Pediatric Indications Elra + RAS Combos in PDAC Elraglusib Oral Tablet Pediatric (NBL + EWS) ○ Elra + RAS Nonclinical Data — 2H 2026 ✓ Phase 1/2 Oral IND — Apr 2026 ✓ BEACON2
Slide 17: Nasdaq Global Market: ACTU
ACTUATE THERAPEUTICS Nasdaq Global Market: ACTU
Actuate Therapeutics — Investor Presentation (September 2026) on 6ix